Galectin Therapeutics
GALT
61 hedge funds and large institutions have $8.05M invested in Galectin Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
3% more funds holding
Funds holding: 59 → 61 (+2)
0.28% more ownership
Funds ownership: 11.69% → 11.97% (+0.28%)
8% less call options, than puts
Call options by funds: $84K | Put options by funds: $91K
29% less capital invested
Capital invested by funds: $11.3M → $8.05M (-$3.26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$87.2K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$84.3K |
| 3 |
Jane Street
New York
|
+$47.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.5K |
| 5 |
VF
Virtu Financial
New York
|
+$35.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
-$53.4K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$42.4K |
| 3 |
STA
Summit Trail Advisors
New York
|
-$39K |
| 4 |
WANY
Wealthspire Advisors (New York)
New York
|
-$28K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$22K |
GALT Hedge Fund Activity: Q4 2022 in Review
61 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2022, worth a combined $8.05M — down 29% from $11.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new GALT positions and 5 closed out — a net gain of 3 holders — while 15 added to existing stakes and 12 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $87.2K. The largest seller was Cutter & Co Brokerage, cutting an estimated $53.4K.
- 61 institutional investors held Galectin Therapeutics (GALT) as of Q4 2022, up from 59 in Q3 2022.
- Funds reported $8.05M of Galectin Therapeutics stock for Q4 2022, down 29% quarter-over-quarter.
- 8 funds opened new Galectin Therapeutics positions in Q4 2022 and 5 closed out, a net change of +3 holders.
- The largest Galectin Therapeutics buyer in Q4 2022 was Citadel Advisors, an estimated $87.2K added.
- The largest Galectin Therapeutics seller in Q4 2022 was Cutter & Co Brokerage, an estimated $53.4K sold.
Based on aggregated 13F filings for Q4 2022.